52 related articles for article (PubMed ID: 9484870)
1. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
Chodosh S; Lakshminarayan S; Swarz H; Breisch S
Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
[TBL] [Abstract][Full Text] [Related]
2. The new fluoroquinolones: A critical review.
Zhanel GG; Walkty A; Vercaigne L; Karlowsky JA; Embil J; Gin AS; Hoban DJ
Can J Infect Dis; 1999 May; 10(3):207-38. PubMed ID: 22346384
[TBL] [Abstract][Full Text] [Related]
3. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
4. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.
MacGowan AP; Bowker KE; Wootton M; Holt HA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1560-4. PubMed ID: 10390203
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
Wise R; Andrews JM
J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
8. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
Felmingham D
J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
Richard MP; Aguado AG; Mattina R; Marre R
J Antimicrob Chemother; 1998 Feb; 41(2):207-14. PubMed ID: 9533462
[TBL] [Abstract][Full Text] [Related]
10. The activity of grepafloxacin against respiratory pathogens in the UK.
Wise R; Andrews JM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
[TBL] [Abstract][Full Text] [Related]
11. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
Appelbaum PC
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
[TBL] [Abstract][Full Text] [Related]
12. Respiratory tract infection: epidemiology and surveillance.
Jacobs MR
J Chemother; 1997 May; 9 Suppl 3():10-7. PubMed ID: 9248976
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
